Tinnitus - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tinnitus - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Tinnitus - Pipeline Review, H2 2016', provides an overview of the Tinnitus pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tinnitus
- The report reviews pipeline therapeutics for Tinnitus by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Tinnitus therapeutics and enlists all their major and minor projects
- The report assesses Tinnitus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Tinnitus

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Tinnitus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Tinnitus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tinnitus Overview 7
Therapeutics Development 8
Pipeline Products for Tinnitus - Overview 8
Pipeline Products for Tinnitus - Comparative Analysis 9
Tinnitus - Therapeutics under Development by Companies 10
Tinnitus - Therapeutics under Investigation by Universities/Institutes 11
Tinnitus - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Tinnitus - Products under Development by Companies 15
Tinnitus - Products under Investigation by Universities/Institutes 16
Tinnitus - Companies Involved in Therapeutics Development 17
AudioCure Pharma GmbH 17
Auris Medical Holding AG 18
Knopp Biosciences LLC 19
Merz Pharma GmbH & Co. KgaA 20
Otonomy, Inc. 21
SciFluor Life Sciences, LLC 22
Sound Pharmaceuticals, Inc. 23
Tinnitus - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 32
AM-102 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AUT-3 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Drug to Activate KCNQ for Tinnitus - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
esketamine hydrochloride - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
gacyclidine SR - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
neramexane mesylate - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
SF-0034 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules for Tinnitus - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SPI-1005 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SPI-3005 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Tinnitus - Dormant Projects 52
Tinnitus - Product Development Milestones 53
Featured News & Press Releases 53
Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus 53
Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million 53
Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus 54
Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus 54
Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus 55
Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City 55
Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus 56
Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311 56
Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311 56
Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio 57
Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience 57
Apr 20, 2015: Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals 58
Mar 13, 2015: Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus 59
Mar 11, 2015: Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City 59
Mar 10, 2015: Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Tinnitus, H2 2016 8
Number of Products under Development for Tinnitus - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Tinnitus - Pipeline by AudioCure Pharma GmbH, H2 2016 17
Tinnitus - Pipeline by Auris Medical Holding AG, H2 2016 18
Tinnitus - Pipeline by Knopp Biosciences LLC, H2 2016 19
Tinnitus - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 20
Tinnitus - Pipeline by Otonomy, Inc., H2 2016 21
Tinnitus - Pipeline by SciFluor Life Sciences, LLC, H2 2016 22
Tinnitus - Pipeline by Sound Pharmaceuticals, Inc., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 31
Tinnitus - Dormant Projects, H2 2016 52